Robert Harrington to Survival Analysis
This is a "connection" page, showing publications Robert Harrington has written about Survival Analysis.
Connection Strength
0.637
-
Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018 04; 198:84-90.
Score: 0.129
-
Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):448-58.
Score: 0.082
-
Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2002 Jan 22; 105(3):322-7.
Score: 0.043
-
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thromb Haemost. 2018 Dec; 118(12):2046-2052.
Score: 0.034
-
Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2018 02; 196:28-35.
Score: 0.032
-
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J. 2014 Dec; 168(6):869-77.e1.
Score: 0.026
-
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.
Score: 0.024
-
Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial. Am Heart J. 2012 May; 163(5):768-776.e2.
Score: 0.022
-
Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. Circulation. 2012 Feb 14; 125(6):749-56.
Score: 0.021
-
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. Am Heart J. 2008 Jul; 156(1):177-84.
Score: 0.016
-
Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. Ann Thorac Surg. 2008 Feb; 85(2):494-9; discussion 499-500.
Score: 0.016
-
Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007 Nov 15; 100(10):1538-42.
Score: 0.016
-
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. Ann Thorac Surg. 2007 Mar; 83(3):993-1001.
Score: 0.015
-
Clinical correlates of long-term mortality after percutaneous interventions of saphenous vein grafts. Am Heart J. 2006 Oct; 152(4):801-6.
Score: 0.015
-
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graft. Circulation. 2006 Jul 04; 114(1 Suppl):I396-401.
Score: 0.015
-
Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol. 2006 Jan 17; 47(2):312-8.
Score: 0.014
-
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005 Nov 16; 294(19):2446-54.
Score: 0.014
-
Early glycoprotein IIb/IIIa inhibitor use for non-ST-segment elevation acute coronary syndrome: patient selection and associated treatment patterns. Acad Emerg Med. 2005 May; 12(5):431-8.
Score: 0.013
-
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005 Mar 01; 95(5):611-4.
Score: 0.013
-
Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005 Mar; 149(3):474-81.
Score: 0.013
-
Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. Am J Cardiol. 2005 Jan 15; 95(2):182-8.
Score: 0.013
-
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA. 2004 Oct 06; 292(13):1555-62.
Score: 0.013
-
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. Can J Cardiol. 2004 Jun; 20(8):773-8.
Score: 0.013
-
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. Am J Med. 2003 Dec 01; 115(8):613-9.
Score: 0.012
-
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.
Score: 0.011